iSpecimen Inc.
NASDAQ Capital MarketTotal Valuation
iSpecimen Inc. carries a market capitalization of 2.29M, placing it among publicly traded companies globally. Its enterprise value stands at -139,313.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.29M |
| Enterprise Value | -139,313.00 |
Share Statistics
iSpecimen Inc. currently has 1.52M shares outstanding.
| Shares Outstanding | 1.52M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.56, and the price-to-book ratio stands at 2.32.
| PE Ratio | N/A |
| PS Ratio | 3.56 |
| PB Ratio | 2.32 |
| P/TBV Ratio | -4.48 |
| P/FCF Ratio | -0.24 |
| P/OCF Ratio | -0.24 |
Enterprise Valuation
| EV / Sales | 5.05 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
iSpecimen Inc. maintains a current ratio of 0.82, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.87, indicating elevated leverage, while an interest coverage ratio of -3,461.09 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.82 |
| Quick Ratio | 0.81 |
| Debt / Equity | 13.87 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -3,461.09 |
Financial Efficiency
| Return on Equity (ROE) | -968.47 |
| Return on Assets (ROA) | -170.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
iSpecimen Inc.'s stock has declined approximately -97.21512% over the past 52 weeks. The 50-day moving average sits at 1.51, while the 200-day moving average is 5.43.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.21512% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 5.43 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, iSpecimen Inc. generated 466,302.00 in revenue and converted that into -11.42M in net income, yielding earnings per share of -18.21. EBITDA reached -8.22M, while operating income came in at -9.42M.
| Revenue | 466,302.00 |
| Gross Profit | -504,830.00 |
| Operating Income | -9.42M |
| Pretax Income | -11.42M |
| Net Income | -11.42M |
| EBITDA | -8.22M |
| EBIT | -9.42M |
| Earnings Per Share (EPS) | -18.21 |
Balance Sheet
iSpecimen Inc. holds 4.41M in cash and equivalents against 240,903.00 in total debt, resulting in a net debt position of -4.41M. Total book value stands at 1.74M, with working capital of -992,538.00 providing operational flexibility.
| Cash & Cash Equivalents | 4.41M |
| Total Debt | 240,903.00 |
| Net Debt | -4.41M |
| Equity (Book Value) | 1.74M |
| Book Value Per Share | 1.14 |
| Working Capital | -992,538.00 |
Cash Flow
iSpecimen Inc. produced -7.00M in operating cash flow over the past twelve months.
| Operating Cash Flow | -7.00M |
| Capital Expenditures | N/A |
| Free Cash Flow | -7.00M |
| FCF Per Share | -11.17 |
Margins
iSpecimen Inc. operates with a gross margin of -108.26, reflecting its pricing power and cost economics. The operating margin of -2,020.04 and net profit margin of -2,449.04 provide insight into operational efficiency.
| Gross Margin | -108.26 |
| Operating Margin | -2,020.04 |
| Pretax Margin | -2,449.04 |
| Profit Margin | -2,449.04 |
| EBITDA Margin | -1,762.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -253.95 |
| FCF Yield | -421.34 |
Stock Splits
iSpecimen Inc.'s most recent stock split took place on April 28, 2026 with a 40:1 split ratio.
| Last Split Date | 4/28/2026 |
| Split Ratio | 40:1 |
Scores
iSpecimen Inc. posts an Altman Z-Score of -31.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -31.57 |